Pfizer completes acquisition of InnoPharma

NEW YORK — Pfizer announced on Thursday that it has completed its acquisition of the pharmaceutical development company, InnoPharma, following receipt of U.S. regulatory approval from all government authorities required by the agreement and other closing conditions.



 “We believe this acquisition will help Pfizer build a strong sterile injectables pipeline in areas such as oncology and central nervous disorders,” said John Young, group president, Pfizer Global Established Pharma. “Sterile injectables is one of several areas of potential growth for GEP. This acquisition reflects our continued view that attractive growth opportunities, both external and organic, exist for the business.”